<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/1202512D-BE7E-496E-90F3-53CEDE1D4E4F"><gtr:id>1202512D-BE7E-496E-90F3-53CEDE1D4E4F</gtr:id><gtr:name>Valevia UK Limited</gtr:name><gtr:address><gtr:line1>Bartholemew Manor
Argyle Road</gtr:line1><gtr:city>Newbury</gtr:city><gtr:postCode>RG14 6BZ</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1202512D-BE7E-496E-90F3-53CEDE1D4E4F" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>1202512D-BE7E-496E-90F3-53CEDE1D4E4F</gtr:id><gtr:name>Valevia UK Limited</gtr:name><gtr:address><gtr:line1>Bartholemew Manor
Argyle Road</gtr:line1><gtr:city>Newbury</gtr:city><gtr:postCode>RG14 6BZ</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>150000.0</gtr:offerGrant><gtr:projectCost>189953.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/39D4676A-CC4C-4DF6-9ACB-0B8AADDDC563"><gtr:id>39D4676A-CC4C-4DF6-9ACB-0B8AADDDC563</gtr:id><gtr:firstName>Nora</gtr:firstName><gtr:surname>Frey</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131276"><gtr:id>E360776F-3EF7-4FA1-959A-A766476F2498</gtr:id><gtr:title>A Novel agent for the treatment of CDifficile infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131276</gtr:grantReference><gtr:abstractText>Clostridium difficile (C.Diff) Associated Diarrhoea (CDAD) is a severe form of diarrhoea which can prove fatal. Prevalence has been increasing since the late 1990s, and it is increasingly occurring outside of hospital and in previously low-risk groups. Valevia is developing a drug which has demonstrated efficacy against hyper-virulent strains of C.Diff and strains with reduced susceptibility to current therapies, is rapidly bactericidal and shows no cross resistance to currently used antibiotic classes. This project will further characterise its pharmacological profile, validate its potential to address currently unmet medical needs in CDAD and design a clinical development plan enabling the earliest possible Registration.</gtr:abstractText><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>150000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131276</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>